On April 12, 2023, Viridian Therapeutics, Inc. (the Company) announced that Carrie Melvin has ceased to serve as the Company's Chief Operating Officer, effective April 11, 2023. In connection with her departure, the Company has agreed to provide Ms. Melvin with severance benefits that would arise from an involuntary not-for cause termination under her employment agreement dated May 25, 2022, subject to Ms. Melvin's execution and non-revocation of a release agreement in favor of the Company and continued compliance with certain restrictive covenants, including covenants relating to confidentiality.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.54 USD | +1.86% | +4.17% | -33.47% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.47% | 911M | |
+33.34% | 49.46B | |
+1.75% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.53% | 26.61B | |
-22.69% | 18.64B | |
+7.82% | 13.16B | |
+29.74% | 12.55B | |
+24.25% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Viridian Therapeutics, Inc. Announces That Carrie Melvin Has Ceased to Serve as the Company’s Chief Operating Officer